Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Operating Expenses (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Operating Expenses for 9 consecutive years, with $29.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 70.95% to $29.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $109.0 million, a 41.56% increase, with the full-year FY2025 number at $109.0 million, up 41.56% from a year prior.
  • Other Operating Expenses was $29.3 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $28.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $29.3 million in Q4 2025 to a low of $3.1 million in Q2 2021.
  • A 5-year average of $13.8 million and a median of $11.4 million in 2023 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 93.86% in 2021, then soared 163.71% in 2022.
  • Ultragenyx Pharmaceutical's Other Operating Expenses stood at $3.5 million in 2021, then skyrocketed by 51.58% to $5.3 million in 2022, then skyrocketed by 122.64% to $11.8 million in 2023, then soared by 44.96% to $17.2 million in 2024, then soared by 70.95% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Operating Expenses are $29.3 million (Q4 2025), $28.0 million (Q3 2025), and $23.0 million (Q2 2025).